BioMarin Pharmaceutical
bmrnNASDAQModerate RiskEnzyme replacement and gene therapy
Market cap
Large cap
Cash position
$1.2B as of Q4 2025
36 months runway
Revenue status
commercial stage
Pipeline assets
3 programs
What does BioMarin Pharmaceutical do?
BioMarin is a well-established rare disease company that has successfully transitioned to commercial profitability. Their flagship product Voxzogo treats achondroplasia with strong uptake worldwide. Their gene therapy Roctavian for hemophilia A received FDA approval but adoption has been slower than expected. The company generates meaningful revenue and is cash flow positive. For investors BMRN represents a lower-risk biotech with real revenue growth though the stock price reflects much of the near-term opportunity. Key questions are whether Voxzogo reaches peak sales and whether Roctavian adoption accelerates.
What to watch
Quarterly Voxzogo revenue growth trajectory
Roctavian treatment center expansion and uptake
BMN 349 Phase 1 safety and PK data
Competitive readouts from Ascendis Pharma
Operating margin expansion as products mature
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Voxzogo | Achondroplasia | Approved | — | ▼ |
| Roctavian | Hemophilia A | Approved | — | ▼ |
| BMN 349 | Complement-mediated diseases | Phase 1 | — | ▼ |
Investment thesis
Bull case
BioMarin has transformed into a profitable rare disease leader with Voxzogo on a strong growth trajectory and peak sales estimates of $2-3B globally. Deep expertise in rare diseases with multiple approved products generating recurring revenue. Pipeline expanding beyond enzyme replacement into gene therapy and small molecules. Strong cash flow with no near-term dilution risk offers rare disease growth with commercial-stage stability.
Bear case
Roctavian uptake disappointing and may never reach peak sales estimates. Voxzogo faces potential competition from Ascendis Pharma TransCon CNP. Rare disease market inherently limited in size. Gene therapy manufacturing remains complex and expensive. Pipeline complement diversification is very early stage with high clinical risk.
Key upcoming catalysts
Voxzogo Q1 2026 revenue update
2026-05-01
Roctavian real-world durability data
2026-06-15
BMN 349 Phase 1 interim data
2026-09-01
Risk factors
Roctavian commercial adoption below expectations
Voxzogo competitive threats from next-gen therapies
Gene therapy manufacturing complexity
Rare disease market size limitations
Regulatory risk for gene therapy label expansions
Comparable companies
Financial snapshot
Cash
$1.2B as of Q4 2025
Quarterly burn
Cash flow positive
Cash runway
36 months
Revenue
commercial stage
Institutional ownership
95%
Sponsored
Get premium bmrn analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you